41 recruiting. 41 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 41 | Recruiting 41 |
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Risankizumab - Crohn Disease, Perianal Fistula | Phase 4 | Recruiting | Yuki Horio | 25 | 2026-10-01 | 2026-10-23 |
| Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi® TyboWe® Adalimumab Injection - Crohn's Disease | Phase 4 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 50 | 2026-09-23 | 2026-09-24 |
| A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically Breast Milk Sample Collection, Guselkumab - Psoriasis, Colitis, Ulcerative | Phase 4 | Recruiting | Janssen Research & Development, LLC | 10 | 2026-08-07 | 2026-11-03 |
| A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication Mirikizumab - Lactation, Inflammatory Bowel Disease | Phase 4 | Recruiting | Eli Lilly and Company | 14 | 2026-08-05 | 2026-09-08 |
| Stopping PPI Therapy in Inactive IBD Continue PPI Therapy, Withdraw PPI Therapy - Ulcerative Colitis (UC), Crohn's Disease | Phase 4 | Recruiting | University of Nottingham | 80 | 2026-07-01 | 2026-07-08 |
| Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study Guselkumab - Crohn Disease (CD), Intensification | Phase 4 | Recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 210 | 2026-06-18 | 2026-06-30 |
| Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease Mirikizumab - IV, Mirikizumab - SC - Crohn Disease (CD) | Phase 4 | Recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 75 | 2026-05-11 | 2026-05-26 |
| GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis Guselkumab, Diet - Pouchitis | Phase 4 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 20 | 2026-04-23 | 2026-05-05 |
| Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD Mirikizumab - Crohn Disease | Phase 4 | Recruiting | Alimentiv Inc. | 60 | 2026-04-20 | 2026-10-26 |
| TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response Upadacitinib, Infliximab Dose Intensification, Adalimumab Dose Intensification - Crohn Disease (CD) | Phase 4 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 312 | 2026-03-01 | 2026-06-09 |
| Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea Rifaximin 200 mg Tablet, Oral Rehydration Therapy (ORT) - Diarrhea, Gastroenteritis | Phase 4 | Recruiting | Bausch Health Americas, Inc. | 54 | 2026-02-11 | 2026-08-13 |
| A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) Guselkumab (GUS) - Crohn Disease | Phase 4 | Recruiting | Xian-Janssen Pharmaceutical Ltd. | 78 | 2025-12-30 | 2026-11-03 |
| Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis Mirikizumab, Azathioprine (AZA) - Ulcerative Colitis (UC) | Phase 4 | Recruiting | University Hospital Schleswig-Holstein | 300 | 2025-12-05 | 2025-12-16 |
| Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety Interleukin 23 - Crohn's Disease and Ulcerative Colitis | Phase 4 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 200 | 2025-12-01 | 2026-04-24 |
| Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment Bismuth, Esomeprazole, Tetracycline - Gastritis, Dyspepsia | Phase 4 | Recruiting | Yongquan Shi | 1248 | 2025-10-28 | 2025-12-02 |
| De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis Ustekinumab 90 mg SC q8w, Ustekinumab 90 mg SC q12w - Crohn Disease (CD), Ulcerative Colitis (UC) | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 115 | 2025-10-08 | 2025-12-26 |
| The Efficacy of Lactobacillous Probiotic and Trace Elements in the Management of Ulcerative Colitis Patients the Patients Will be Recruited From Outpatient Clinic of Inflammatory Bowel Disease (IBD) of the National Hepatology and Tropical Medicine Research Institute NHTMRI, Cairo, Egypt Lactobacillus acidophilus will be assigned for arm 1, trace elements, Control Arm - standard of care - Ulcerative Colitis (UC) | Phase 4 | Recruiting | National Hepatology & Tropical Medicine Research Institute | 132 | 2025-07-02 | 2026-09-16 |
| APPI-Cost Trial for Perforated Appendicitis PVI, Usual Care - Perforated Appendicitis | Phase 4 | Recruiting | The University of Texas Health Science Center, Houston | 346 | 2025-04-07 | 2025-12-11 |
| Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial Vonoprazan, Tetracycline 500mg tid, Minocycline - Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer | Phase 4 | Recruiting | Yongquan Shi | 400 | 2025-04-01 | 2025-08-14 |
| Efficacy of Melatonin Treatment on Sleep Quality Improvement in Inflammatory Bowel Disease Patients With Clinical Remission Melatonin ("Circadin"), Placebo - IBD (Inflammatory Bowel Disease) | Phase 4 | Recruiting | Mahidol University | 90 | 2025-04-01 | 2026-08-04 |
Showing 20 of 41. Sign in to see all of them.
Crohn Disease (22) · Colitis, Ulcerative (15) · Inflammatory Bowel Diseases (3) · Stomach Neoplasms (3) · Appendicitis (2) · Dyspepsia (2) · Gastritis (2) · Peptic Ulcer (2) · Pouchitis (2) · Abdominal Abscess (1) · Arthritis, Psoriatic (1) · Bacterial Infections (1) · Breast Feeding (1) · Deglutition Disorders (1) · Diarrhea (1)
Digestive System Diseases (41) · Gastrointestinal Diseases (41) · Intestinal Diseases (38) · Inflammatory Bowel Diseases (29) · Colitis (15) · Colonic Diseases (15) · Pathological Conditions, Signs and Symptoms (4) · Digestive System Neoplasms (3) · Gastrointestinal Neoplasms (3) · Infections (3) · Neoplasms (3) · Neoplasms by Site (3) · Signs and Symptoms (3) · Signs and Symptoms, Digestive (3)
Infliximab (6) · vedolizumab (6) · Adalimumab (4) · guselkumab (4) · Ustekinumab (3) · mirikizumab (3) · Bismuth (2) · Rifaximin (2) · Tablets (2) · Tetracycline (2) · risankizumab (2) · upadacitinib (2) · 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (1) · Adrenal Cortex Hormones (1) · Amoxicillin (1)
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (3) · Sixth Affiliated Hospital, Sun Yat-sen University (3) · Alimentiv Inc. (2) · Bausch Health Americas, Inc. (2) · Children's Hospital of Fudan University (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Universitaire Ziekenhuizen KU Leuven (2) · Yongquan Shi (2) · Asan Medical Center (1) · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Centre Hospitalier Universitaire, Amiens (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Eli Lilly and Company (1) · International Agency for Research on Cancer (1)
China (12) · United States (10) · Canada (6) · France (6) · Belgium (4) · Germany (3) · Italy (3) · Poland (3) · Denmark (2) · United Kingdom (2) · Australia (1) · Czechia (1) · Egypt (1) · Israel (1) · Japan (1)
Ying Huang (2) · Annick Moens, MD, PhD (1) · Byong Duk Ye, MD, PhD (1) · Dalya Ferguson, MD, MS (1) · Edward Barnes, MD, MPH (1) · Jin Young Park, PhD (1) · Julajak Limsrivilai, MD (1) · Marc Ferrante, Professor (1) · Marcis Leja, MD, PhD (1)
PMID 28801429, PMID 34519690, PMID 40243391, PMID 40357993, PMID 41720589, PMID 42141850
2025 (4), 2023 (1), K12TR004908 (1), R03DK140415 (1)